ID: ALA3618494

Max Phase: Preclinical

Molecular Formula: C54H66O31

Molecular Weight: 1211.09

Molecule Type: Small molecule

Representations

Canonical SMILES:  C[C@@H]1O[C@@H](O[C@@H]2CO[C@@H](Oc3c(O)cc(C4=C(O[C@@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O[C@@H]5O[C@H](COC(=O)/C=C/c6ccc(O)cc6)[C@@H](O)[C@H](O)[C@H]5O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(=O)c5c(O)cc(O)cc5C4)cc3O)[C@H](O)[C@H]2O)[C@H](O)[C@H](O)[C@H]1O

Standard InChI:  InChI=1S/C54H66O31/c1-17-33(62)39(68)44(73)51(77-17)80-30-16-76-50(43(72)37(30)66)83-47-26(59)11-20(12-27(47)60)24-10-21-9-23(57)13-25(58)32(21)38(67)46(24)82-53-48(41(70)34(63)18(2)78-53)85-54-49(84-52-45(74)40(69)35(64)28(14-55)79-52)42(71)36(65)29(81-54)15-75-31(61)8-5-19-3-6-22(56)7-4-19/h3-9,11-13,17-18,28-30,33-37,39-45,48-60,62-66,68-74H,10,14-16H2,1-2H3/b8-5+/t17-,18-,28+,29+,30+,33-,34-,35+,36+,37-,39+,40-,41+,42-,43+,44+,45+,48+,49+,50-,51-,52-,53-,54-/m0/s1

Standard InChI Key:  HFLPEIGRXJDZGY-BPXGVSJSSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 1211.09

Molecular Weight (Monoisotopic): 1210.3588

AlogP:

#Rotatable Bonds:

Polar Surface Area:

Molecular Species:

HBA:

HBD:

#RO5 Violations:

HBA (Lipinski):

HBD (Lipinski):

#RO5 Violations (Lipinski):

CX Acidic pKa:

CX Basic pKa:

CX LogP:

CX LogD:

Aromatic Rings:

Heavy Atoms:

QED Weighted:

Np Likeness Score:

References

1. Al-Asri J, Fazekas E, Lehoczki G, Perdih A, Görick C, Melzig MF, Gyémánt G, Wolber G, Mortier J..  (2015)  From carbohydrates to drug-like fragments: Rational development of novel α-amylase inhibitors.,  23  (20): [PMID:26395057] [10.1016/j.bmc.2015.09.007]

Source

Source(1):

• Scientific Literature